From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment.

IF 2 Q2 ECONOMICS

PharmacoEconomics Open Pub Date : 2024-11-12 DOI:10.1007/s41669-024-00542-2

Ferrario Lucrezia, Menzaghi Barbara, Rizzardini Giuliano, Roccia Alessandro, Garagiola Elisabetta, Bellavia Daniele, Schettini Fabrizio, Foglia Emanuela

{"title":"From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment.","authors":"Ferrario Lucrezia, Menzaghi Barbara, Rizzardini Giuliano, Roccia Alessandro, Garagiola Elisabetta, Bellavia Daniele, Schettini Fabrizio, Foglia Emanuela","doi":"10.1007/s41669-024-00542-2","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study was to define the economic and organizational impacts related to a broader utilization of bictegravir/emtricitabine/alafenamide (BIC/FTC/TAF) in Italian clinical practice.Methods: A budget impact analysis-representing the evolution of the Italian National Healthcare Service (NHS) healthcare expenditure over 3 years-was developed, considering the overall Italian population treated for human immunodeficiency virus (HIV). Model input variables were treatment history, therapeutic regimen, development of adverse events, achievement of an undetectable viral load and total direct healthcare costs. Besides the BIA, an organizational impact assessment was conducted to determine the impact on the use of healthcare resources, assessing the release of organizational hospital assets, focusing on the management of drug-related adverse events. Data were collected from scientific evidence, Italian national and regional legislations and healthcare professionals' reports. To verify the robustness of the economic and organizational impact assessment, sensitivity analyses were performed.Results: Results demonstrate economic savings of about 26 million euros in total health spending, assuming a higher penetration rate for BIC/FTC/TAF. This change in the current case mix would lead to a reduction in the specific costs related to adverse event management (0.9 million euros; - 2.09%) and in the medical management of patients (38 million euros; - 7.79%), with a positive impact on the achievement of virological control. From an organizational perspective, a wider use of BIC/FTC/TAF generates a reduction in the utilization of healthcare resources due to a decrease in adverse events and complications. The model estimated a 19.64% reduction in HIV-related inpatient days, which freed up healthcare professional time.Conclusions: Capable of improving both economic and organizational sustainability for the entire HIV care continuum, BIC/FTC/TAF is an efficient therapeutic strategy for people with HIV.","PeriodicalId":19770,"journal":{"name":"PharmacoEconomics Open","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41669-024-00542-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of this study was to define the economic and organizational impacts related to a broader utilization of bictegravir/emtricitabine/alafenamide (BIC/FTC/TAF) in Italian clinical practice.

Methods: A budget impact analysis-representing the evolution of the Italian National Healthcare Service (NHS) healthcare expenditure over 3 years-was developed, considering the overall Italian population treated for human immunodeficiency virus (HIV). Model input variables were treatment history, therapeutic regimen, development of adverse events, achievement of an undetectable viral load and total direct healthcare costs. Besides the BIA, an organizational impact assessment was conducted to determine the impact on the use of healthcare resources, assessing the release of organizational hospital assets, focusing on the management of drug-related adverse events. Data were collected from scientific evidence, Italian national and regional legislations and healthcare professionals' reports. To verify the robustness of the economic and organizational impact assessment, sensitivity analyses were performed.

Results: Results demonstrate economic savings of about 26 million euros in total health spending, assuming a higher penetration rate for BIC/FTC/TAF. This change in the current case mix would lead to a reduction in the specific costs related to adverse event management (0.9 million euros; - 2.09%) and in the medical management of patients (38 million euros; - 7.79%), with a positive impact on the achievement of virological control. From an organizational perspective, a wider use of BIC/FTC/TAF generates a reduction in the utilization of healthcare resources due to a decrease in adverse events and complications. The model estimated a 19.64% reduction in HIV-related inpatient days, which freed up healthcare professional time.

Conclusions: Capable of improving both economic and organizational sustainability for the entire HIV care continuum, BIC/FTC/TAF is an efficient therapeutic strategy for people with HIV.

查看原文本刊更多论文

艾滋病治疗中从临床到非临床的结果：经济和组织影响评估》。

研究目的本研究旨在确定在意大利临床实践中更广泛地使用比特拉韦/恩曲他滨/阿拉非那胺（BIC/FTC/TAF）对经济和组织的影响：方法：考虑到意大利接受人类免疫缺陷病毒（HIV）治疗的总人口，我们开发了一项预算影响分析，反映了意大利国家医疗保健服务（NHS）医疗保健支出在 3 年内的变化情况。模型输入变量包括治疗史、治疗方案、不良事件的发生、检测不到病毒载量的实现情况以及直接医疗费用总额。除 BIA 外，还进行了组织影响评估，以确定对医疗资源使用的影响，评估医院组织资产的释放情况，重点关注药物相关不良事件的管理。数据来自科学证据、意大利国家和地区立法以及医疗保健专业人员的报告。为验证经济和组织影响评估的稳健性，进行了敏感性分析：结果表明，假设 BIC/FTC/TAF 的普及率较高，则在医疗总支出方面可节省约 2600 万欧元的经济支出。目前病例组合的这一变化将导致与不良事件处理（90 万欧元；- 2.09%）和患者医疗管理（3800 万欧元；- 7.79%）相关的具体费用减少，并对实现病毒控制产生积极影响。从组织角度来看，由于不良事件和并发症的减少，更广泛地使用 BIC/FTC/TAF 可以降低医疗资源的使用率。该模型估计，与艾滋病相关的住院天数减少了 19.64%，从而节省了医护人员的时间：结论：BIC/FTC/TAF 能够改善整个艾滋病治疗过程中的经济和组织可持续性，对艾滋病患者来说是一种高效的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PharmacoEconomics Open Multiple-

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： PharmacoEconomics - Open focuses on applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. The journal includes, but is not limited to, the following research areas:Economic analysis of healthcare interventionsHealth outcomes researchCost-of-illness studiesQuality-of-life studiesAdditional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in PharmacoEconomics -Open may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.